Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Recruiting now · Phase 4

Conditions studied: Multiple Myeloma

In brief

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

Key facts

Study ID

NCT06057402

Run by

Pfizer

People needed

80

Starts

2023-10-03

Expected to finish

2032-02-22

Last updated by the study team

2026-07-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must agree to follow the reproductive criteria as outlined in the protocol
• Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).

You may not qualify if…

• Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
• Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.

Where it is running

• Taipei Veterans General Hospital — Taipei, Taiwan (enrolling)
• UC Irvine Health — Orange, California, United States (enrolling)
• UCI Health — Orange, California, United States (enrolling)
• UCHealth Poudre Valley Hospital — Fort Collins, Colorado, United States (enrolling)
• UCHealth Harmony — Fort Collins, Colorado, United States (enrolling)
• UCHealth Greeley Hospital — Greeley, Colorado, United States (enrolling)
• Longs Peak Hospital — Longmont, Colorado, United States (enrolling)
• UCHealth Longs Peak Medical Center — Longmont, Colorado, United States (enrolling)
• UCHealth - Medical Center of the Rockies — Loveland, Colorado, United States (enrolling)
• Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center — Coral Gables, Florida, United States (enrolling)
• University of Miami Hospital and Clinics Deerfield Beach — Deerfield Beach, Florida, United States (enrolling)
• Sylvester Comprehensive Cancer Center — Miami, Florida, United States (enrolling)
• University of Miami Hospital and Clinics - Griffin Cancer Research Building — Miami, Florida, United States (enrolling)
• University of Miami Hospital and Clinics — Miami, Florida, United States (enrolling)
• University of Michigan — Ann Arbor, Michigan, United States (enrolling)
• Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion) — Detroit, Michigan, United States (enrolling)
• St. David's South Austin Medical Center — Austin, Texas, United States (enrolling)
• Epworth Freemasons — Melbourne, Victoria, Australia (enrolling)
• Epworth Hospital — Richmond, Victoria, Australia (enrolling)
• Slade Pharmacy — Richmond, Victoria, Australia (enrolling)
• Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta, Canada (enrolling)
• Cross Cancer Institute — Edmonton, Alberta, Canada (enrolling)
• McGill University Health Centre — Montreal, Quebec, Canada (enrolling)
• National Taiwan University Hospital — Taipei, Taiwan (enrolling)
• UCI Health - Irvine Infusion Pharmacy ACC — Irvine, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.